COMP <GO>
LKFT vs SEPN // EV/EBITDA & P/E VALUATION
Lakefront Biotherapeutics (NASDAQ) VS. Septerna Inc. (NASDAQ) • 15-METRIC TALLY: LKFT 2
— SEPN 0
■ METRIC PARITY
LAST: $32.33 (+0.78%) • MKT CAP: $2.13B
valuation
—
LAST: $45.23 (+2.22%) • MKT CAP: $2.11B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LKFT VS. SEPN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LKFT | SEPN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -20.70% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 5.19% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.87 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 6/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.8 | 65.2 | +4.62 | LKFT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.13B | $2.11B | $19.3M | LKFT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LKFT REV | SEPN REV | LKFT GROSS % | SEPN GROSS % | LKFT FCF | SEPN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $46.0M | — | — | — | $109.7M |
| FY 2024 | — | $1.1M | — | — | — | -$69.6M |
| FY 2023 | — | $151.0K | — | — | — | -$38.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LKFT // BETA —
SEPN // BETA —